{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-205405","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2024-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.016335+00:00","generated_at":"2026-05-31T07:57:48.894675+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioMarin R&D chief Henry Fuchs to retire March 2025; Greg Friberg to succeed","bullets":["Dr. Henry J. Fuchs to retire from BioMarin effective March 3, 2025.","Dr. Greg Friberg to assume EVP, Chief Worldwide R&D Officer role on September 30, 2024.","Fuchs will serve as senior advisor from October 1, 2024 until retirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-205405","json":"https://secwatch.observer/filing/0001193125-24-205405.json","markdown":"https://secwatch.observer/filing/0001193125-24-205405.md","text":"https://secwatch.observer/filing/0001193125-24-205405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312524205405/0001193125-24-205405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312524205405/d880241d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:57:48.894675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2011baba62","claim":"Henry J. Fuchs retired as Executive Vice President, Chief Worldwide Research and Development Officer at BIOMARIN PHARMACEUTICAL INC.","evidence_excerpt":"On August 16, 2024, Dr. Henry J. Fuchs advised BioMarin Pharmaceutical Inc. (the “Company”) that he has elected to retire from the Company effective March 3, 2025 (the “Retirement Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312524205405/0001193125-24-205405-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Executive Vice President, Chief Worldwide Research and Development Officer"}]},{"claim_id":"631a33841d","claim":"Greg Friberg was appointed as Executive Vice President, Chief Worldwide Research and Development Officer at BIOMARIN PHARMACEUTICAL INC.","evidence_excerpt":"He will continue in his current role until Dr. Greg Friberg assumes the position of Executive Vice President, Chief Worldwide Research and Development Officer, which is expected on September 30, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312524205405/0001193125-24-205405-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, Chief Worldwide Research and Development Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}